Elacridar – 5 mg

Brand:
Cayman
CAS:
143664-11-3
Storage:
-20
UN-No:
Non-Hazardous - /

Elacridar is a dual inhibitor of P-glycoprotein (MRP-1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). It maximally inhibits P-glycoprotein in isolated human peripheral blood leukocytes at 200 nM.{29372} Elacridar blocks the activity of P-glycoprotein at the blood-brain barrier, altering the pharmacokinetics of certain drugs in the brain.{29371} This compound is effective against both human BCRP and the mouse homolog, Bcrp1.{29369,29370}  

 

Available on backorder

SKU: - Category:

Description

A dual inhibitor of MRP-1 and BCRP; maximally inhibits MRP-1 in isolated human peripheral blood leukocytes at 200 nM; effective against both human BCRP and the mouse homolog, Bcrp1


Formal name: N-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-4-acridinecarboxamide

Synonyms:  GF120918|GG918|GW0918

Molecular weight: 563.6

CAS: 143664-11-3

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Transporter & Exchanger Modulators||Research Area|Cancer|Multidrug Resistance||Research Area|Toxicology|Drug Metabolism